UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of medical therapies on inflammatory bowel disease complication rate

World journal of gastroenterology : WJG, 2012-08, Vol.18 (29), p.3823-3827

2012

Volltextzugriff (PDF)

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

Journal of Crohn's and colitis, 2013-03, Vol.7 (2), p.154-160

2013

Volltextzugriff (PDF)

Early Post-Operative Endoscopy Is Associated with Lower Surgical Recurrence of Crohn’s Disease: A Retrospective Study of Three Successive Cohorts

Gastroenterology research and practice, 2022-11, Vol.2022, p.1-9

2022

Volltextzugriff (PDF)

Do clinical factors help to predict disease course in inflammatory bowel disease?

World journal of gastroenterology : WJG, 2010-06, Vol.16 (21), p.2600-2603

2010

Volltextzugriff (PDF)

Anti-TNF Monotherapy for Crohn’s Disease: a 13-year Multicentre Experience

Journal of Crohn's and colitis, 2016-05, Vol.10 (5), p.516-524

2016

Volltextzugriff (PDF)

Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy

Inflammatory bowel diseases, 2016-06, Vol.22 (6), p.1362-1369

2016

Volltextzugriff (PDF)

Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study

Infection prevention in practice, 2023-03, Vol.5 (1), p.100267-100267, Article 100267

2023

Volltextzugriff (PDF)

Anti-TNF and Crohn's disease: when should we stop?

Current drug targets, 2010-02, Vol.11 (2), p.148-151

2010

Volltextzugriff (PDF)

Progressing Towards the Implementation of a Treat-To-Target Strategy in Perianal Crohn’s Disease

Journal of Crohn's and colitis, 2022-06, Vol.16 (5), p.693-694

2022

Volltextzugriff (PDF)

Essential reading from the editor's desk

Acta gastro-enterologica belgica, 2021-07, Vol.84 (3), p.399-400

2021

Volltextzugriff (PDF)

Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort

Digestive and liver disease, 2021-01, Vol.53 (1), p.72-78

2021

Volltextzugriff (PDF)

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

Alimentary pharmacology & therapeutics, 2012-12, Vol.36 (11-12), p.1040-1048

2012

Volltextzugriff (PDF)

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Inflammatory bowel diseases, 2024-02, Vol.30 (2), p.240-246

2024

Volltextzugriff (PDF)

Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study

Clinical gastroenterology and hepatology, 2024-05

2024

Volltextzugriff (PDF)

Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring

Gut, 2013-12, Vol.62 (12), p.1806-1816

2013

Volltextzugriff (PDF)

Mesenchymal Stem Cell Injection in Crohn’s Disease Strictures: A Phase I–II Clinical Study

Journal of Crohn's and colitis, 2022-03, Vol.16 (3), p.506-510

2022

Volltextzugriff (PDF)

Risk of Late Postoperative Recurrence of Crohn’s Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers

Clinical gastroenterology and hepatology, 2021-06, Vol.19 (6), p.1218-1225.e4

2021

Volltextzugriff (PDF)

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice

United European Gastroenterology Journal, 2018-10, Vol.6 (8), p.1117-1125

2018

Volltextzugriff (PDF)

Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations

Journal of Crohn's and colitis, 2015-08, Vol.9 (8), p.685-691

2015

Volltextzugriff (PDF)

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Inflammatory bowel diseases, 2018-04, Vol.24 (5), p.1099-1105

2018

Volltextzugriff (PDF)

Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission

Clinical gastroenterology and hepatology, 2018-02, Vol.16 (2), p.234-243.e2

2018

Volltextzugriff (PDF)

Review: Current directions of biologic therapies in inflammatory bowel disease

Therapeutic Advances in Gastroenterology, 2010-03, Vol.3 (2), p.99-106

2010

Volltextzugriff (PDF)

Sa1115 Natural History of Non-Severe Inflammatory Bowel Diseases At Diagnosis

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-203-S-204

2014

Volltextzugriff (PDF)

Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients

Digestive and liver disease, 2017-09, Vol.49 (9), p.991-996

2017

Volltextzugriff (PDF)

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(101)

Publikationsform

Sprache

Englisch
(106)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of medical therapies on inflammatory bowel disease complication rate

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

Early Post-Operative Endoscopy Is Associated with Lower Surgical Recurrence of Crohn’s Disease: A Retrospective Study of Three Successive Cohorts

Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease

Do clinical factors help to predict disease course in inflammatory bowel disease?

Anti-TNF Monotherapy for Crohn’s Disease: a 13-year Multicentre Experience

Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy

Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study

Anti-TNF and Crohn's disease: when should we stop?

Progressing Towards the Implementation of a Treat-To-Target Strategy in Perianal Crohn’s Disease

Essential reading from the editor's desk

Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study

Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring

Mesenchymal Stem Cell Injection in Crohn’s Disease Strictures: A Phase I–II Clinical Study

Risk of Late Postoperative Recurrence of Crohn’s Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice

Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission

Review: Current directions of biologic therapies in inflammatory bowel disease

Sa1115 Natural History of Non-Severe Inflammatory Bowel Diseases At Diagnosis

Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients

Suchergebnisse filtern